Literature DB >> 23998059

A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ Cell Counts and Disease Progression in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era.

K V Ramana1, V Sabitha, Ratna Rao.   

Abstract

INTRODUCTION: Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has been a challenge to medical fraternity since it was first discovered in 1983. About 40 million people are living with HIV infection globally and 99% of the infected people are in south East Asia (SEA). Traditionally, HIV disease and progression, initiation of HAART and response to therapy is monitored by assessing in regular intervals, the T CD4+ cell counts and plasma HIV/RNA viral load. Resource poor, low and low - middle income group countries still have no finances to acquire infrastructure and scientific technology for performing such tests.
OBJECTIVES: Since very few studies are available, they have demonstrated the role of alternate biomarkers that can be used to predict CD4 cell counts and thereby, monitor HIV disease progression and HAART. We aimed to measure certain haematological parameters in HIV seropositive patients and to evaluate their efficacy in predicting TCD4+ cell counts.
METHODS: The study group included 250 HIV seropositive patients with an age range of 18-65 years. 140(56%) males and 110(44%) females were included in the study. Absolute TCD4+cell counts and CD8+T cell counts were measured by using a flow cytometer. (MMWR Recommendations and Reports, 1992) TLC; HB%, AEC and ESR were estimated by using conventional haematological methods. CRP was evaluated by latex agglutination test (Immuno CRP Latex Agglutination Test).
RESULTS: Among the tested haematological markers, a TLC of <1800 cells/mm(3) showed high specificity (100%) in predicting CD4 counts of < 200 cells/mm(3), with an accuracy of 61.46%. Haemoglobin and Absolute Eosinophilic counts showed high specificities of 84.09% and 94.32% respectively in predicting CD4 counts which were below 350 cells/mm(3). ESR with 98.98% sensitivity and AEC which had 83.67% sensitivity were able to predict CD4 counts of <200 cells/mm(3).
CONCLUSION: Among the tested biomarkers, it was seen that Absolute Eosinophilic counts of more than 550 cells/mm(3), Blood Haemoglobin which was less than 10 g%, ESR which measured more than 20 mm, CRP values of >1.2 and TLC of <1800 cells/mm(3) could be helpful in predicting CD4 cell counts of < 350 and <200 cells/mm(3).

Entities:  

Keywords:  Alternate biomarkers; HAART; Human Immunodeficiency Virus (HIV)

Year:  2013        PMID: 23998059      PMCID: PMC3749629          DOI: 10.7860/JCDR/2013/5306.3138

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  19 in total

1.  Risk factors and correlates for anemia in HIV treatment-naïve infected patients: a cross-sectional analytical study.

Authors:  José A Mata-Marín; Jesús E Gaytán-Martínez; Rosa E Martínez-Martínez; Carla I Arroyo-Anduiza; José L Fuentes-Allen; Moisés Casarrubias-Ramirez
Journal:  BMC Res Notes       Date:  2010-08-20

2.  Total lymphocyte count is a good marker for HIV-related mortality and can be used as a tool for starting HIV treatment in a resource-limited setting.

Authors:  Helena P W Oudenhoven; Hinta Meijerink; Rudi Wisaksana; Suryani Oetojo; Agnes Indrati; Andre J A M van der Ven; Henri A G H van Asten; Bachti Alisjahbana; Reinout van Crevel
Journal:  Trop Med Int Health       Date:  2011-09-01       Impact factor: 2.622

3.  Prevalence of anaemia and immunological markers among ghanaian HAART-naïve HIV-patients and those on HAART.

Authors:  W K B A Owiredu; L Quaye; N Amidu; O Addai-Mensah
Journal:  Afr Health Sci       Date:  2011-03       Impact factor: 0.927

4.  Eosinophilia in patients infected with human immunodeficiency virus.

Authors:  A J Cohen; R T Steigbigel
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

5.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

6.  Relation between erythrocyte sedimentation rate, clinical and immune status in HIV-infected patients.

Authors:  M A Ndakotsu; L Salawu; M A Durosinmi
Journal:  Niger J Med       Date:  2009 Apr-Jun

7.  Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population.

Authors:  Susan C Morpeth; John A Crump; Humphrey J Shao; Habib O Ramadhani; Peter R Kisenge; Cindy A Moylan; Susanna Naggie; L Brett Caram; Keren Z Landman; Noel E Sam; Dafrosa K Itemba; John F Shao; John A Bartlett; Nathan M Thielman
Journal:  AIDS Res Hum Retroviruses       Date:  2007-10       Impact factor: 2.205

8.  Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda.

Authors:  Steven Baveewo; Francis Ssali; Charles Karamagi; Joan N Kalyango; Judith A Hahn; Kenneth Ekoru; Peter Mugyenyi; Elly Katabira
Journal:  PLoS One       Date:  2011-05-12       Impact factor: 3.240

9.  Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study.

Authors:  David R Boulware; David B Meya; Tracy L Bergemann; Darin L Wiesner; Joshua Rhein; Abdu Musubire; Sarah J Lee; Andrew Kambugu; Edward N Janoff; Paul R Bohjanen
Journal:  PLoS Med       Date:  2010-12-21       Impact factor: 11.069

Review 10.  Current practices in laboratory monitoring of HIV infection.

Authors:  Madhu Vajpayee; Teena Mohan
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

View more
  1 in total

Review 1.  Stem cell-based therapies for HIV/AIDS.

Authors:  Olivier Pernet; Swati Seth Yadav; Dong Sung An
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.